FSD Pharma Inc.

HUGE

CA35954B4047

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 02:25:56 2024-04-25 pm EDT			5-day change	1st Jan Change
0.66 ^CAD	0.00%		+3.12%	-45.00%

Apr. 25	FSD Pharma Says Celly Nutrition Partners with Six+One for US Launch of Dietary Supplement	MT
Apr. 08	FSD Pharma Receives Nasdaq Non-Compliance Notice	MT

FSD PHARMA INC ANNOUNCES ANNUAL GENERAL MEETING OF SHAREHOLDERS

June 15, 2022 at 08:56 am EDT

FSD PHARMA INC announces that an Annual General Meeting of Shareholders will be held on 23 June, 2022 - 1:00 PM (EDT).

Contact:

Investor

Email: ir@fsdpharma.com

E: info@fsdpharma.com

Website: www.fsdpharma.com

Latest news about FSD Pharma Inc.

FSD Pharma Says Celly Nutrition Partners with Six+One for US Launch of Dietary Supplement	Apr. 25	MT
FSD Pharma Receives Nasdaq Non-Compliance Notice	Apr. 08	MT
FSD Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
FSD Pharma Edging Up In US Premarket Trade As Signs Agreement With iNGENu CRO	Mar. 27	MT
FSD Pharma Brief: Signed Agreement With iNGENu CRO To Conduct a Clinical Study To Assess Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults	Mar. 27	MT
FSD Pharma Brief: Submitting a Phase-1b Clinical Trial Application for its Proprietary Beverage unbuzzd	Mar. 11	MT
FSD Pharma Inc. Submits A Phase-1B Clinical Trial Application for Ethics Committee for Its Proprietary Beverage Unbuzzd	Mar. 11	CI
FSD Pharma Presents "Positive" Phase 1 Lucid-21-302 Results at ACTRIMS Forum	Mar. 05	MT
Refile-- FSD Pharma Brief: Presenting "Positive" Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum	Mar. 05	MT
FSD Pharma Brief: Presenting "Positive: Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum	Mar. 05	MT
FSD Pharma Inc. Presents Positive Results on First-In-Human Phase-1 Study of Lucid-21-302 (Lucid-Ms) At Americas Committee for Treatment and Research in Multiple Sclerosis 2024 Forum	Mar. 05	CI
MT Newswires Canada Stocks To Watch: SSR Mining, Tricon Residential; Imperial Oil; FSD Pharma	Feb. 19	MT
Reflile: FSD Pharma Up 3.7% In US Premarket As Says Court of Appeal Dismissed Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Near $3 Million	Feb. 06	MT
FSD Pharma Up 3.7$ In US Premarket As Says Court of Appeal Dismissed Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Near $3 Million	Feb. 06	MT
FSD Pharma Brief: Says Court of Appeal Dismissed Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million	Feb. 06	MT
FSD Pharma Inc. Announces Board Changes	Jan. 29	CI
FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus	Dec. 27	MT
FSD Pharma Inc. announced that it has received CAD 0.000046 million in funding	Dec. 04	CI
FSD Pharma Inc. completed the Spin-Off of Celly Nutrition Corp.	Nov. 28	CI
FSD Pharma Inc. announced that it expects to receive CAD 0.000046 million in funding	Nov. 26	CI
FSD Pharma Inc. Announces Change of CEO	Nov. 16	CI
FSD Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
FSD Pharma Enters Agreement on Distribution of Portion of Celly Nutrition Shareholdings	23-10-05	MT
FSD Pharma Inc. agreed to Spin-Off 34.66% stake of Celly Nutrition Corp.	23-10-03	CI
FSD Pharma Shares Rise After Saying Interim Report Shows Multiple Sclerosis Treatment Candidate Safe, Well-Tolerated	23-09-18	MT

FSD Pharma Inc. is a Canada-based biotechnology company. The Company operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Companyâs two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Companyâs Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial real estate property. Lucid-PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
FSD PHARMA INC.	-45.00%	19.33M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	103B
REGENERON PHARMACEUTICALS, INC.	+1.41%	95.71B
ARGENX SE	+0.76%	22.02B
BIONTECH SE	-17.84%	20.9B
GENMAB A/S	-9.35%	17.85B
WUXI APPTEC CO., LTD.	-42.83%	16.21B
BEIGENE, LTD.	-17.63%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.86B
SAREPTA THERAPEUTICS, INC.	+32.11%	12.04B